Aside from ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and healthy enough to tolerate FCR therapy, should be good candidates for that latter, Along with the reward remaining this procedure might be accomplished in 6 months when ibrutinib must be taken indefinitely. This feature would be notably beneficial for non-compliant people